JP2009538282A - 乏突起膠細胞の生存を促進させるためのNogo受容体−1(NgR1)アンタゴニストの使用 - Google Patents

乏突起膠細胞の生存を促進させるためのNogo受容体−1(NgR1)アンタゴニストの使用 Download PDF

Info

Publication number
JP2009538282A
JP2009538282A JP2009511015A JP2009511015A JP2009538282A JP 2009538282 A JP2009538282 A JP 2009538282A JP 2009511015 A JP2009511015 A JP 2009511015A JP 2009511015 A JP2009511015 A JP 2009511015A JP 2009538282 A JP2009538282 A JP 2009538282A
Authority
JP
Japan
Prior art keywords
ngr1
seq
polypeptide
antibody
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538282A5 (cg-RX-API-DMAC7.html
Inventor
ジェーン ケー. レルトン,
ミンウェイ リー,
ベンシウ チー,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2009538282A publication Critical patent/JP2009538282A/ja
Publication of JP2009538282A5 publication Critical patent/JP2009538282A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2009511015A 2006-05-15 2007-05-15 乏突起膠細胞の生存を促進させるためのNogo受容体−1(NgR1)アンタゴニストの使用 Pending JP2009538282A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80000806P 2006-05-15 2006-05-15
PCT/US2007/011557 WO2007133746A2 (en) 2006-05-15 2007-05-15 Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival

Publications (2)

Publication Number Publication Date
JP2009538282A true JP2009538282A (ja) 2009-11-05
JP2009538282A5 JP2009538282A5 (cg-RX-API-DMAC7.html) 2010-07-08

Family

ID=38694527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511015A Pending JP2009538282A (ja) 2006-05-15 2007-05-15 乏突起膠細胞の生存を促進させるためのNogo受容体−1(NgR1)アンタゴニストの使用

Country Status (4)

Country Link
US (1) US20110123535A1 (cg-RX-API-DMAC7.html)
EP (1) EP2023735A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009538282A (cg-RX-API-DMAC7.html)
WO (1) WO2007133746A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502623A (ja) * 2006-08-31 2010-01-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド Nogoレセプターポリペプチドの末梢投与に関する方法
WO2009114197A2 (en) * 2008-03-13 2009-09-17 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014311A2 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
WO2006002437A2 (en) * 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving demyelination

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341050C (en) * 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0396719B1 (en) * 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
WO1998002452A2 (en) * 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
US5858708A (en) * 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
CA2331154A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
US20030113325A1 (en) * 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
FR2900996B1 (fr) * 2006-05-12 2008-08-08 Skf Ab Cage pour roulement a billes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014311A2 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
WO2006002437A2 (en) * 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving demyelination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012032523; Neuron Vol.45, 2005, p.353-359 *

Also Published As

Publication number Publication date
WO2007133746A3 (en) 2008-03-20
WO2007133746A2 (en) 2007-11-22
US20110123535A1 (en) 2011-05-26
EP2023735A4 (en) 2011-05-25
EP2023735A2 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
US8642040B2 (en) Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
CN101918540B (zh) Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
JP5829373B2 (ja) Nogoレセプターアンタゴニスト
JP5773879B2 (ja) 神経系の細胞の生存を促進するためのDR6およびp75のアンタゴニストの使用
US9068992B2 (en) Screening methods for identifying Sp35 antagonists
JP2013166795A (ja) ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法
JP2009513666A (ja) 希乏突起神経膠細胞−ミエリン糖タンパク質組成物およびその使用方法
US20110123535A1 (en) Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival
CN1972707B (zh) 涉及脱髓鞘的疾病的治疗
HK1103978B (en) Treatment of conditions involving demyelination
HK1146596B (en) Use of lingo-4 antagonists in the treatment of conditions involving demyelination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130111